The Evolution of Patient-Reported Outcomes from Clinical Trial Outcomes to Clinical Care and their Future in Precision Medicine
08 March 2017 12:00 to 13:00 EST
250 MA, Auditorium
Speaker: John Spertus, MD, MPH, FAHA, FACC Missouri/Lauer Endowed Chair and Tenured Professor University of Missouri-Kansas City Clinical Director, Outcomes Research Saint Luke’s Mid America Heart Institute
Seminar Abstract: To provide an overview of patient-reported outcomes in heart failure and then to demonstrate how these can serve as outcomes in clinical trials and as the foundation for translating precision medicine to the bedside as a means for maximizing the translation of clinical trials to clinical practice.
Entry instructions: There is no cost to attend the seminar. If you are interested in attending please contact Meghan Spencer. Please check in with security at the Novartis visitor's entrance of 220 Massachusetts Avenue and you will be directed to the location of the seminar.
Speaker | John Spertus, MD, MPH, FAHA, FACC
John Spertus is a cardiologist and the Lauer/Missouri Endowed Chair and Professor of Medicine at the University of Missouri-Kansas City, where he serves as Clinical Director of Outcomes Research at Saint Luke’s Mid America Heart Institute. He is a graduate of UCSF Medical School and completed his internal medicine, cardiology and health services training at the University of Washington. His research activities led to his induction into the American Society of Clinical Investigation in 2006, his receipt of the AHA Quality of Care and Outcomes Research Council’s Distinguished Achievement Award, being named by Thompson Reuters as one of the most influential scientists in the world in 2014 and again in 2015, and being awarded the AHA QCOR Lifetime Achievement Award in 2015.
Dr. Spertus has devoted his career to improving the quality of cardiovascular care. His research focuses on methods for assessing patients’ health outcomes, measuring healthcare quality, and the use of information technology to guide medical decision-making based on risk-prediction models so that treatment can be safer, more cost-effective, evidence-based and patient-centered. He developed the Seattle Angina Questionnaire (SAQ), and the Kansas City Cardiomyopathy Questionnaire (KCCQ), which have both been translated into over 90 languages each and are emerging as the gold standards for measuring patients’ symptoms, function and quality of life in coronary artery disease and heart failure. While he collaborates with basic scientists to illuminate the prognostic significance of genetics and biomarkers on cardiovascular outcomes, his primary focus in the translational research enterprise is at the interface of patient care.